<DOC>
	<DOCNO>NCT00447330</DOCNO>
	<brief_summary>The purpose study evaluate progression free survival capecitabine ( Xeloda ) , oxaliplatin bevacizumab ( Avastin ) previously untreated metastatic esophagogastric adenocarcinoma .</brief_summary>
	<brief_title>Oxaliplatin , Capecitabine Avastin Metastatic Esophagogastric Adenocarcinoma</brief_title>
	<detailed_description>The number new case esophageal gastric cancer United States 2005 14520 esophageal cancer 21860 gastric cancer . Unfortunately , esophageal gastric cancer also account 13570 11550 death , respectively , 2005 . The 5 year survival rate metastatic gastroesophageal , GE junctional , gastric cancer less 5 % . The major current treatment modality patient advanced esophageal , GE junctional , gastric adenocarcinomas systemic chemotherapy . We seek investigate efficacy capecitabine oxaliplatin combination bevacizumab first line treatment metastatic esophagogastric cancer . The choice capecitabine oxaliplatin make develop user-friendly biologically-based regimen , offer patient oral capecitabine place continuous 5FU infusion pump . Since capecitabine give crushed regimen may active user-friendly . Preliminary data colorectal cancer suggest regimen capecitabine , oxaliplatin , bevacizumab comparable activity FOLFOX-bevacizumab . The goal propose regimen define capecitabine oxaliplatin-based regimen optimize biological approach cytotoxic approach . The addition bevacizumab chemotherapy regimens metastatic colorectal cancer , metastatic non-small cell lung cancer , metastatic breast cancer show improve response rate overall survival . If active , regimen could serve first line comparator capecitabine , oxaliplatin , epirubicin combination . This approach also help simplify regimen development across gastrointestinal cancer . In addition primary efficacy endpoint protocol , several correlative endpoint also examine exploratory manner . The importance develop blood-based tumor biomarkers extensively review . However , role predictive marker well study XELOX-A . This information important since may help define population likely benefit likely suffer significant toxicity important GI cancer regimen . This biomarker approach may also help understand define mechanism sensitivity , resistance , toxicity may use guide future hypothesis-driven study design improve efficacy safety regimen . The correlative biomarker endpoint include serum , plasma urine biomarkers ( e.g . VEGF bFGF ) , wind heal model angiogenesis , tumor biopsy study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Primary Histologically cytologically document radiographically measurable adenocarcinoma esophagus stomach metastatic/recurrent amenable potentially curative treatment No prior therapy metastatic disease Prior radiation therapy permit , provide complete &gt; 28 day prior day 1 study drug Normal organ marrow function Karnofsky Performance Status 70100 % Primary Unstable poorly control hypertension &gt; 150/100 mm Hg Arterial thromboembolic event within 6 month Clinically significant uncontrolled cardiac disease Significant proteinuria baseline Grade 2 great peripheral neuropathy History abdominal fistula , GI perforation , intraabdominal abscess within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>metastatic esophagogastric adenocarcinoma</keyword>
	<keyword>ESOPHAGEAL CANCER</keyword>
	<keyword>GASTRIC CANCER</keyword>
	<keyword>ADENOCARCINOMA</keyword>
	<keyword>TARGTED THERAPY</keyword>
	<keyword>BEVACIZUMAB</keyword>
	<keyword>CAPECITBAINE</keyword>
	<keyword>OXALIPLATIN</keyword>
	<keyword>METASTATIC</keyword>
</DOC>